1. Home
  2. NTLA vs VTEX Comparison

NTLA vs VTEX Comparison

Compare NTLA & VTEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • VTEX
  • Stock Information
  • Founded
  • NTLA 2014
  • VTEX 1999
  • Country
  • NTLA United States
  • VTEX Cayman Islands
  • Employees
  • NTLA N/A
  • VTEX N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • VTEX Computer Software: Prepackaged Software
  • Sector
  • NTLA Health Care
  • VTEX Technology
  • Exchange
  • NTLA Nasdaq
  • VTEX Nasdaq
  • Market Cap
  • NTLA 1.2B
  • VTEX 1.1B
  • IPO Year
  • NTLA 2016
  • VTEX 2021
  • Fundamental
  • Price
  • NTLA $12.06
  • VTEX $4.08
  • Analyst Decision
  • NTLA Buy
  • VTEX Buy
  • Analyst Count
  • NTLA 20
  • VTEX 4
  • Target Price
  • NTLA $32.30
  • VTEX $7.83
  • AVG Volume (30 Days)
  • NTLA 4.2M
  • VTEX 1.8M
  • Earning Date
  • NTLA 08-07-2025
  • VTEX 11-04-2025
  • Dividend Yield
  • NTLA N/A
  • VTEX N/A
  • EPS Growth
  • NTLA N/A
  • VTEX 48.79
  • EPS
  • NTLA N/A
  • VTEX 0.05
  • Revenue
  • NTLA $52,857,000.00
  • VTEX $230,497,000.00
  • Revenue This Year
  • NTLA $8.32
  • VTEX $11.14
  • Revenue Next Year
  • NTLA N/A
  • VTEX $15.19
  • P/E Ratio
  • NTLA N/A
  • VTEX $78.06
  • Revenue Growth
  • NTLA 14.99
  • VTEX 4.53
  • 52 Week Low
  • NTLA $5.90
  • VTEX $3.92
  • 52 Week High
  • NTLA $23.76
  • VTEX $7.58
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 60.10
  • VTEX 31.34
  • Support Level
  • NTLA $11.29
  • VTEX $3.94
  • Resistance Level
  • NTLA $12.46
  • VTEX $4.15
  • Average True Range (ATR)
  • NTLA 0.56
  • VTEX 0.14
  • MACD
  • NTLA 0.12
  • VTEX 0.07
  • Stochastic Oscillator
  • NTLA 84.85
  • VTEX 52.38

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

Share on Social Networks: